Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00044902 | Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade) | PHASE2 | COMPLETED | - | — | — | - | - | Dec 28, 2007 | - | — |
| Name | Type | Description |
|---|---|---|
| epratuzumab | DRUG | - |
* Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL \* Received and failed at least 1 prior regimen of chemotherapy \* Rituximab-naive or received prior rituximab in their last treatment (single agent or in combination with chemotherapy) and demonstrated a time to progression of at le...